Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Yidu TechFRA:0EL -0.40%72 Debt-to-EBITDA is 0.35 as of Mar. 2026. GuruFocus rates FRA:0EL with a GF Score™ of 72/100 and a GF Value™ of €0.67 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 481 Healthcare Providers & Services companies, Yidu Tech ranks better than 73.6% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Yidu Tech's Debt-to-EBITDA or its related term are showing as below:
FRA:0EL'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.45 Med: -0.3 Max: 0.82
Current: 0.82
During the past 9 years, the highest Debt-to-EBITDA Ratio of Yidu Tech was 0.82. The lowest was -1.45. And the median was -0.30.
FRA:0EL's Debt-to-EBITDA is ranked better than 73.6% of 481
companies
in the Healthcare Providers & Services industry
Industry Median: 2.19
vs FRA:0EL: 0.82
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Yidu Tech Debt-to-EBITDA Related Terms
Yidu Tech Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Yidu Tech's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:0EL vs VEEV, BTSG, HQY: Debt-to-EBITDA Comparison
For the Health Information Services subindustry, Yidu Tech's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yidu Tech Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Yidu Tech's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Yidu Tech's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Mar. 2026) EBITDA data.
Yidu Tech (FRA:0EL) has a Debt-to-EBITDA of 0.35 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Yidu Tech. According to the industry distribution chart, Yidu Tech ranks #127 out of 481 companies in the Healthcare Providers & Services industry, placing it in the top 26.4%.
Is Yidu Tech's Debt-to-EBITDA too high?
Yidu Tech's current Debt-to-EBITDA is 0.35. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.19. Yidu Tech's value of 0.35 is 84% below this industry median. Based on the distribution chart, Yidu Tech ranks #127 out of 481 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Yidu Tech has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Yidu Tech's Debt-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Yidu Tech ranks #127 out of 481 companies for Debt-to-EBITDA. This puts Yidu Tech in the upper half of its industry. The industry median Debt-to-EBITDA is 2.19. Yidu Tech's value of 0.35 is 84% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.19, based on 481 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Yidu Tech's current Debt-to-EBITDA of 0.35 is 84% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Yidu Tech. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yidu Tech's current Debt-to-EBITDA is 0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yidu Tech stock overvalued right now?
Based on GuruFocus' analysis, Yidu Tech (FRA:0EL) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.67, compared to a current price of €0.50 — trading 25.7% below its estimated fair value. The current Debt-to-EBITDA is 0.35 and 84% below the Healthcare Providers & Services industry median of 2.19. Yidu Tech's overall GF Score™ is 72/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Yidu Tech (FRA:0EL), the current Debt-to-EBITDA is 0.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Yidu Tech (FRA:0EL) Overvalued in 2026?
Based on GuruFocus' analysis, Yidu Tech stock appears to be undervalued.
The current stock price of €0.50 is trading 25.7% below its estimated GF Value™ of €0.67.
GuruFocus considers Yidu Tech to be Modestly Undervalued.
Key valuation signals for FRA:0EL:
Debt-to-EBITDA: 0.35
GF Value™: €0.67 vs. price of €0.50 (25.7% below fair value)
Industry Position: 84% below the Healthcare Providers & Services median (#127 of 481)
No single metric tells the full story. See the FRA:0EL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Yidu Tech Inc offers healthcare solutions built on big data and artificial intelligence (AI) technologies. The company serves various healthcare industry participants, including hospitals, pharmaceutical, biotech, research institutions, insurance companies, etc. Its operating segments are: Big data platform and solutions, Life sciences solutions, and Health management platform and solutions. The majority of the company's revenue is generated from its Big data platform and solutions segment, which provides data intelligence platforms and data analytics-driven solutions (such as Eywa 5.0, Lingxi Intelligent Management, AI Middleware, etc.) for hospitals, healthcare institutions, regulators, and policymakers. Geographically, the company generates maximum revenue from Mainland China.
72GF Score
Get the complete analysis for FRA:0EL
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0EL has been successfully added to your 
